SCHEMBL3498917

SCHEMBL3498917

CCCCOc1ccccc1N1CCN(C(Cc2ccc(C#N)c(Oc3cccc(C)n3)c2)c2cnc(C)[nH]2)CC1=O

nearest known ligand 0.34

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.34
FNTA P49354 8/20 0.33
FNTB P49356 8/20 0.33
PGGT1B P53609 6/20 0.33
BCAT2 O15382 1/20 0.32
BCAT1 P54687 1/20 0.32
P2RX3 P56373 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7527027 0.99 FFAR4 (0.33) FFAR4FNTAFNTBPGGT1BBCAT2
SCHEMBL3499837 0.87 FNTA (0.44) FNTAFNTBPGGT1BBCAT2BCAT1
SCHEMBL7566917 0.87 BCAT2 (0.32) BCAT2BCAT1
Hydrochloric Acid SCHEMBL7588892 0.86 FNTA (0.44) FNTAFNTBPGGT1BBCAT2BCAT1
SCHEMBL7689761 0.84 FFAR4 (0.35) FFAR4
SCHEMBL7690259 0.81 FFAR4 (0.35) FFAR4
SCHEMBL7688314 0.81 FFAR4 (0.35) FFAR4
SCHEMBL7690630 0.79 FFAR4 (0.35) FFAR4
SCHEMBL3498916 0.77 FNTA (0.45) FNTAFNTBPGGT1BP2RX3
SCHEMBL7685752 0.77 HTT (0.42) FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1744751-A2 METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2007-01-24 EP claimed
US-20050277629-A1 Methods for the treatment of synucleinopathies (Lansbury) THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2005-12-15 US claimed
WO-2005089502-A2 METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2005-09-29 WO claimed
US-20020010184-A1 Inhibitors of prenyl-protein transferase DINSMORE CHRISTOPHER J (US) 2002-01-24 US claimed
US-20110294794-A1 TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR LINK MEDICINE CORPORATION (US) 2011-12-01 US disclosed
US-20100184803-A1 Treatment of Lysosomal Storage Diseases LINK MEDICINE CORPORATION (MA) 2010-07-22 US disclosed
US-20070293539-A1 Methods for the treatment of synucleinopathies NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2007-12-20 US disclosed
US-20050277629-A1 Methods for the treatment of synucleinopathies (Lansbury) THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2005-12-15 US disclosed
US-20020010184-A1 Inhibitors of prenyl-protein transferase DINSMORE CHRISTOPHER J (US) 2002-01-24 US disclosed
WO-2001060368-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010184-A1 Inhibitors of prenyl-protein transferase FNTA, FNTB, ZMPSTE24 FFAR4 3612/4885FNTA 1/4885FNTB 2/4885
US-20100184803-A1 Treatment of Lysosomal Storage Diseases GAA, GBA1, MAN2B1 FFAR4 2501/4885FNTA 19/4885FNTB 24/4885
US-20070293539-A1 Methods for the treatment of synucleinopathies SNCA, PARK7, NLN FFAR4 3917/4885FNTA 24/4885FNTB 49/4885
US-20050277629-A1 Methods for the treatment of synucleinopathies (Lansbury) SNCA, PARK7, NLN FFAR4 4000/4885FNTA 12/4885FNTB 44/4885
US-20110294794-A1 TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR FNTA, FNTB, BDNF FFAR4 1344/4885FNTA 1/4885FNTB 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.